423 related articles for article (PubMed ID: 12885347)
1. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study.
Flotte TR; Zeitlin PL; Reynolds TC; Heald AE; Pedersen P; Beck S; Conrad CK; Brass-Ernst L; Humphries M; Sullivan K; Wetzel R; Taylor G; Carter BJ; Guggino WB
Hum Gene Ther; 2003 Jul; 14(11):1079-88. PubMed ID: 12885347
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease.
Aitken ML; Moss RB; Waltz DA; Dovey ME; Tonelli MR; McNamara SC; Gibson RL; Ramsey BW; Carter BJ; Reynolds TC
Hum Gene Ther; 2001 Oct; 12(15):1907-16. PubMed ID: 11589832
[TBL] [Abstract][Full Text] [Related]
3. Repeated delivery of adeno-associated virus vectors to the rabbit airway.
Beck SE; Jones LA; Chesnut K; Walsh SM; Reynolds TC; Carter BJ; Askin FB; Flotte TR; Guggino WB
J Virol; 1999 Nov; 73(11):9446-55. PubMed ID: 10516053
[TBL] [Abstract][Full Text] [Related]
4. Spliceosome-mediated RNA trans-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells.
Liu X; Luo M; Zhang LN; Yan Z; Zak R; Ding W; Mansfield SG; Mitchell LG; Engelhardt JF
Hum Gene Ther; 2005 Sep; 16(9):1116-23. PubMed ID: 16149910
[TBL] [Abstract][Full Text] [Related]
5. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications.
Joseph PM; O'Sullivan BP; Lapey A; Dorkin H; Oren J; Balfour R; Perricone MA; Rosenberg M; Wadsworth SC; Smith AE; St George JA; Meeker DP
Hum Gene Ther; 2001 Jul; 12(11):1369-82. PubMed ID: 11485629
[TBL] [Abstract][Full Text] [Related]
6. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies.
Wagner JA; Nepomuceno IB; Messner AH; Moran ML; Batson EP; Dimiceli S; Brown BW; Desch JK; Norbash AM; Conrad CK; Guggino WB; Flotte TR; Wine JJ; Carter BJ; Reynolds TC; Moss RB; Gardner P
Hum Gene Ther; 2002 Jul; 13(11):1349-59. PubMed ID: 12162817
[TBL] [Abstract][Full Text] [Related]
7. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung.
Conrad CK; Allen SS; Afione SA; Reynolds TC; Beck SE; Fee-Maki M; Barrazza-Ortiz X; Adams R; Askin FB; Carter BJ; Guggino WB; Flotte TR
Gene Ther; 1996 Aug; 3(8):658-68. PubMed ID: 8854091
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of a recombinant adeno-associated virus 5-pseudotyped cystic fibrosis transmembrane conductance regulator vector.
Sirninger J; Muller C; Braag S; Tang Q; Yue H; Detrisac C; Ferkol T; Guggino WB; Flotte TR
Hum Gene Ther; 2004 Sep; 15(9):832-41. PubMed ID: 15353038
[TBL] [Abstract][Full Text] [Related]
9. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.
Moss RB; Rodman D; Spencer LT; Aitken ML; Zeitlin PL; Waltz D; Milla C; Brody AS; Clancy JP; Ramsey B; Hamblett N; Heald AE
Chest; 2004 Feb; 125(2):509-21. PubMed ID: 14769732
[TBL] [Abstract][Full Text] [Related]
10. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus.
Harvey BG; Leopold PL; Hackett NR; Grasso TM; Williams PM; Tucker AL; Kaner RJ; Ferris B; Gonda I; Sweeney TD; Ramalingam R; Kovesdi I; Shak S; Crystal RG
J Clin Invest; 1999 Nov; 104(9):1245-55. PubMed ID: 10545523
[TBL] [Abstract][Full Text] [Related]
11. [Aerosol administration of a replication defective recombinant adenovirus expressing normal human cDNA-CFTR in the respiratory tractus in patients with cystic fibrosis].
Bellon G; Calmard L; Thouvenot D; Levrey H; Jagneaux V; Poitevin F; Malcus C; Accart N; Séné C; Layani MP; Aymard M; Bienvenu J; Courtney M; Döring G; Gilly B; Gilly R; Lamy D; Morel Y; Paulin C; Perraud F; Rodillon L; So S; Touraine F; Schatz C; Pavirani A
C R Seances Soc Biol Fil; 1996; 190(1):109-42. PubMed ID: 8881273
[TBL] [Abstract][Full Text] [Related]
12. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.
Wagner JA; Messner AH; Moran ML; Daifuku R; Kouyama K; Desch JK; Manley S; Norbash AM; Conrad CK; Friborg S; Reynolds T; Guggino WB; Moss RB; Carter BJ; Wine JJ; Flotte TR; Gardner P
Laryngoscope; 1999 Feb; 109(2 Pt 1):266-74. PubMed ID: 10890777
[TBL] [Abstract][Full Text] [Related]
13. Recombinant adeno-associated virus vectors for cystic fibrosis gene therapy.
Flotte TR
Curr Opin Mol Ther; 2001 Oct; 3(5):497-502. PubMed ID: 11699895
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus 5-fiber 35 chimeric vector mediates efficient apical correction of the cystic fibrosis transmembrane conductance regulator defect in cystic fibrosis primary airway epithelia.
Granio O; Ashbourne Excoffon KJ; Henning P; Melin P; Norez C; Gonzalez G; Karp PH; Magnusson MK; Habib N; Lindholm L; Becq F; Boulanger P; Zabner J; Hong SS
Hum Gene Ther; 2010 Mar; 21(3):251-69. PubMed ID: 19788389
[TBL] [Abstract][Full Text] [Related]
15. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis.
Hyde SC; Southern KW; Gileadi U; Fitzjohn EM; Mofford KA; Waddell BE; Gooi HC; Goddard CA; Hannavy K; Smyth SE; Egan JJ; Sorgi FL; Huang L; Cuthbert AW; Evans MJ; Colledge WH; Higgins CF; Webb AK; Gill DR
Gene Ther; 2000 Jul; 7(13):1156-65. PubMed ID: 10918483
[TBL] [Abstract][Full Text] [Related]
16. Vector-specific complementation profiles of two independent primary defects in cystic fibrosis airways.
Zhang Y; Jiang Q; Dudus L; Yankaskas JR; Engelhardt JF
Hum Gene Ther; 1998 Mar; 9(5):635-48. PubMed ID: 9551612
[TBL] [Abstract][Full Text] [Related]
17. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium.
Perricone MA; Morris JE; Pavelka K; Plog MS; O'Sullivan BP; Joseph PM; Dorkin H; Lapey A; Balfour R; Meeker DP; Smith AE; Wadsworth SC; St George JA
Hum Gene Ther; 2001 Jul; 12(11):1383-94. PubMed ID: 11485630
[TBL] [Abstract][Full Text] [Related]
18. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector.
Flotte TR; Afione SA; Conrad C; McGrath SA; Solow R; Oka H; Zeitlin PL; Guggino WB; Carter BJ
Proc Natl Acad Sci U S A; 1993 Nov; 90(22):10613-7. PubMed ID: 7504271
[TBL] [Abstract][Full Text] [Related]
19. Species-specific differences in mouse and human airway epithelial biology of recombinant adeno-associated virus transduction.
Liu X; Yan Z; Luo M; Engelhardt JF
Am J Respir Cell Mol Biol; 2006 Jan; 34(1):56-64. PubMed ID: 16195538
[TBL] [Abstract][Full Text] [Related]
20. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line.
Kearns WG; Afione SA; Fulmer SB; Pang MC; Erikson D; Egan M; Landrum MJ; Flotte TR; Cutting GR
Gene Ther; 1996 Sep; 3(9):748-55. PubMed ID: 8875221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
